Print this page
radiation
-
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/ Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients.
Protocol: 032410Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Pilot Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial.
Protocol: 032411Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab
Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small
Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1
Expression
Protocol: 032502Principal Investigator:
- Sivraj Muralikrishnan
Applicable Disease Sites: Lung -
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer.
Protocol: 032507Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer.
Protocol: 042208Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.
Protocol: 042405Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative
(HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor.
Protocol: 042502Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
An Open-Label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician's Choice in Hormone Receptor-Positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer.
Protocol: 042503Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast -
Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.
Protocol: 042504Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer.
Protocol: 042506Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer Using ctDNA and HARPS Biomarker Assay.
Protocol: 042507Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast